Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
有前途的試驗結果顯示癌症治療和診斷的新標準即將到來。
On Friday, Pfizer Inc (NYSE:PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ:MRNA) and Merck & Co (NYSE:MRK) also reported durable efficiency of their combined melanoma treatment that consists of an experimental mRNA vaccine and Merck's blockbuster immunotherapy, Keytruda.
週五，輝瑞公司（NYSE:PFE）透露其治療一種先進形式的肺癌的藥物在晚期試驗中顯示出長期有希望的結果。週一，Moderna（納斯達克:MRNA）和默沙東公司（紐交所:MRK）也報告了他們的聯合黑色素瘤治療的持久有效率，該治療包括一種實驗性的mRNA疫苗和默沙東的暢銷的免疫治療藥Keytruda。
Pfizer Is Aiming To Set The Treatment Standard For Lung Cancer
輝瑞旨在爲肺癌設定治療標準
With encouraging results, Pfizer is getting another step closer to establish its drug as the new standard treatment for lung cancer. Lorbrena has helped patients live longer without their cancer...
隨着令人鼓舞的結果，輝瑞離將其藥物確立爲新的肺癌標準治療又進...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。